

Europe Cancer Immunotherapy Market - Industry Trends and Forecast to 2033

Market Report | 2023-12-01 | 348 pages | Data Bridge Market Research

AVAILABLE LICENSES:

- Single User License \$3500.00
- Corporate Users License \$4200.00

Report description:

The Europe cancer immunotherapy market is expected to reach USD 49,512.88 million by 2031 from USD 18,921.43 million in 2023, growing at a CAGR of 13.7% during the forecast period of 2024 to 2031.

Market Segmentation

Europe Cancer Immunotherapy Market, By Product Type (Checkpoint Inhibitors, Monoclonal Antibodies, Vaccines, Cell Therapies, Immunomodulators, and Oncolytic Virus), Application (Lung Cancer, Breast Cancer, Melanoma, Myeloma, Prostate Cancer, Ovarian Cancer, Cervical Cancer, Stomach Cancer, Colorectal Cancer, Head & Neck Cancer, and Others), End User (Hospitals, Oncology Clinics, Homecare, and Others), Form (Intravenous (IV), Intramuscular, and Oral), Distribution Channel (Direct Tenders, Retail Sales, and Pharmacies), Country (Germany, France, U.K., Italy, Russia, Spain, Turkey, Belgium, Netherlands, Switzerland, Denmark, and Rest of Europe) - Industry Trends and Forecast to 2031

Overview of Europe Cancer Immunotherapy Market Dynamics

Driver

- Rising prevalence of cancer incidences

Restraint

- Increasing occurrence of immune-related adverse events

Opportunity

- Growing trend towards combination therapies

Market Players

Some of the major market players operating in the Europe cancer immunotherapy market are:

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com

- Merck & Co., Inc.
- F. Hoffmann-La Roche Ltd
- Bristol-Myers Squibb Company
- Janssen Pharmaceutical
- AstraZeneca
- Gilead Sciences, Inc.
- Eli Lilly and Company
- Amgen Inc.
- Novartis AG
- GSK
- Pfizer Inc.
- Incyte

Table of Contents:

TABLE OF CONTENTS	
1 INTRODUCTION	83
1.1 OBJECTIVES OF THE STUDY	83
1.2 MARKET DEFINITION	83
1.3 OVERVIEW OF THE EUROPE CANCER IMMUNOTHERAPY MARKET	83
1.4 CURRENCY AND PRICING	85
1.5 LIMITATIONS	85
1.6 MARKETS COVERED	85
2 MARKET SEGMENTATION	89
2.1 MARKETS COVERED	89
2.2 GEOGRAPHICAL SCOPE	90
2.3 YEARS CONSIDERED FOR THE STUDY	91
2.4 DBMR TRIPOD DATA VALIDATION MODEL	92
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS	95
2.6 MULTIVARIATE MODELLING	96
2.7 PRODUCT TYPE SEGMENT LIFELINE CURVE	96
2.8 MARKET END USER COVERAGE GRID	97
2.9 DBMR MARKET POSITION GRID	98
2.10 VENDOR SHARE ANALYSIS	99
2.11 SECONDARY SOURCES	100
2.12 ASSUMPTIONS	100
3 EXECUTIVE SUMMARY	101
4 PREMIUM INSIGHTS	103
4.1 PESTAL ANALYSIS	104
4.2 PORTERS 5 FORCES	105
5 EUROPE CANCER IMMUNOTHERAPY MARKET: REGULATIONS	106
6 MARKET OVERVIEW	114
6.1 DRIVERS	116
6.1.1 RISING PREVALENCE OF CANCER INCIDENCES	116
6.1.2 RISING TECHNOLOGICAL ADVANCEMENTS	116
6.1.3 INCREASED UNDERSTANDING OF TUMOR MICROENVIRONMENT	117

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

6.1.4 RISE IN PATIENT AWARENESS AND DEMAND FOR TARGETED TREATMENT	117
6.2 RESTRAINTS	118
6.2.1 INCREASING OCCURRENCE OF IMMUNE-RELATED ADVERSE EVENTS	118
6.2.2 DEVELOPING RESISTANCE TO CANCER TREATMENT	118
6.3 OPPORTUNITIES	119
6.3.1 GROWING TREND TOWARDS COMBINATION THERAPIES	119
6.3.2 RISING INTEGRATION OF ARTIFICIAL INTELLIGENCE AND DIGITAL HEALTH TOOLS	119
6.3.3 DEVELOPMENT OF NEXT-GENERATION IMMUNOTHERAPIES	120
6.4 CHALLENGES	121
6.4.1 LACK OF STANDARDIZATION IN BIOMARKER TESTING	121
6.4.2 COMPLEXITY OF DEVELOPING AND IMPLEMENTING PERSONALIZED MEDICINE	121
7 EUROPE CANCER IMMUNOTHERAPY MARKET , BY PRODUCT TYPE	122
7.1 OVERVIEW	123
7.2 CHECKPOINT INHIBITORS	126
7.2.1 PROGRAMMED DEATH 1 (PD-1) & PROGRAMMED DEATH LIGAND 1 (PD-L1)	127
7.2.2 CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN-4 (CTLA-4)	127
7.3 MONOCLONAL ANTIBODIES	128
7.3.1 NAKED MONOCLONAL ANTIBODIES	129
7.3.2 CONJUGATED MONOCLONAL ANTIBODIES	129
7.3.3 BISPECIFIC MONOCLONAL ANTIBODIES	129
7.4 VACCINES	130
7.4.1 PROPHYLACTIC VACCINES	131
7.4.2 THERAPEUTIC VACCINES	131
7.5 CELL THERAPIES	131
7.5.1 CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY	132
7.5.2 T CELL THERAPY	132
7.6 IMMUNOMODULATORS	132
7.6.1 INTERFERONS	133
7.6.2 INTERLEUKINS	133
7.6.3 GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR	133
7.7 ONCOLYTIC VIRUS	134
8 EUROPE CANCER IMMUNOTHERAPY MARKET , BY END USER	135
8.1 OVERVIEW	136
8.2 HOSPITALS	139
8.3 ONCOLOGY CLINICS	140
8.4 HOMECARE	140
8.5 OTHERS	141
9 EUROPE CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL	142
9.1 OVERVIEW	143
9.2 DIRECT TENDERS	146
9.3 RETAIL SALES	147
9.4 PHARMACIES	147
9.4.1 HOSPITAL	148
9.4.2 RETAIL	148
9.4.3 ONLINE	148
10 EUROPE CANCER IMMUNOTHERAPY MARKET, BY FORM	149
10.1 OVERVIEW	150

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.2 INTRAVENOUS (IV) 153
- 10.3 INTRAMUSCULAR 154
- 10.4 ORAL 154
- 11 EUROPE CANCER IMMUNOTHERAPY MARKET, BY APPLICATION 155
 - 11.1 OVERVIEW 156
 - 11.2 LUNG CANCER 159
 - 11.2.1 CHECKPOINT INHIBITORS 160
 - 11.2.2 MONOCLONAL ANTIBODIES 160
 - 11.2.3 CELL THERAPIES 160
 - 11.2.4 IMMUNOMODULATORS 160
 - 11.3 BREAST CANCER 161
 - 11.3.1 CHECKPOINT INHIBITORS 161
 - 11.3.2 MONOCLONAL ANTIBODIES 161
 - 11.3.3 CELL THERAPIES 162
 - 11.3.4 IMMUNOMODULATORS 162
 - 11.4 MELANOMA 162
 - 11.4.1 CHECKPOINT INHIBITORS 163
 - 11.4.2 MONOCLONAL ANTIBODIES 163
 - 11.4.3 CELL THERAPIES 163
 - 11.4.4 IMMUNOMODULATORS 163
 - 11.4.5 ONCOLYTIC VIRUS 163
 - 11.5 MULTIPLE MYELOMA 164
 - 11.5.1 CHECKPOINT INHIBITORS 164
 - 11.5.2 MONOCLONAL ANTIBODIES 164
 - 11.5.3 CELL THERAPIES 164
 - 11.5.4 IMMUNOMODULATORS 165
 - 11.6 PROSTATE CANCER 165
 - 11.6.1 CHECKPOINT INHIBITORS 165
 - 11.6.2 MONOCLONAL ANTIBODIES 166
 - 11.6.3 CELL THERAPIES 166
 - 11.6.4 IMMUNOMODULATORS 166
 - 11.6.5 VACCINES 166
 - 11.7 OVARIAN CANCER 166
 - 11.7.1 CHECKPOINT INHIBITORS 167
 - 11.7.2 MONOCLONAL ANTIBODIES 167
 - 11.7.3 CELL THERAPIES 167
 - 11.7.4 IMMUNOMODULATORS 167
 - 11.8 CERVICAL CANCER 168
 - 11.8.1 CHECKPOINT INHIBITORS 168
 - 11.8.2 MONOCLONAL ANTIBODIES 168
 - 11.8.3 VACCINES 169
 - 11.8.4 CELL THERAPIES 169
 - 11.8.5 IMMUNOMODULATORS 169
 - 11.9 STOMACH CANCER 169
 - 11.9.1 CHECKPOINT INHIBITORS 170
 - 11.9.2 MONOCLONAL ANTIBODIES 170
 - 11.9.3 CELL THERAPIES 170

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.9.4 IMMUNOMODULATORS 170
- 11.10 COLORECTAL CANCER 170
 - 11.10.1 CHECKPOINT INHIBITORS 171
 - 11.10.2 MONOCLONAL ANTIBODIES 171
 - 11.10.3 CELL THERAPIES 171
 - 11.10.4 IMMUNOMODULATORS 171
- 11.11 HEAD AND NECK CANCER 172
 - 11.11.1 CHECKPOINT INHIBITORS 172
 - 11.11.2 MONOCLONAL ANTIBODIES 172
 - 11.11.3 CELL THERAPIES 172
 - 11.11.4 IMMUNOMODULATORS 173
- 11.12 OTHERS 173
 - 11.12.1 CHECKPOINT INHIBITORS 173
 - 11.12.2 MONOCLONAL ANTIBODIES 173
 - 11.12.3 VACCINES 174
 - 11.12.4 CELL THERAPIES 174
 - 11.12.5 IMMUNOMODULATORS 174
- 12 EUROPE CANCER IMMUNOTHERAPY MARKET, BY REGION 175
 - 12.1 EUROPE 177
 - 12.1.1 GERMANY 185
 - 12.1.2 FRANCE 193
 - 12.1.3 ITALY 201
 - 12.1.4 SPAIN 209
 - 12.1.5 U.K. 217
 - 12.1.6 SWITZERLAND 225
 - 12.1.7 NETHERLANDS 233
 - 12.1.8 RUSSIA 241
 - 12.1.9 TURKEY 249
 - 12.1.10 POLAND 257
 - 12.1.11 HUNGARY 265
 - 12.1.12 LITHUANIA 273
 - 12.1.13 AUSTRIA 281
 - 12.1.14 IRELAND 289
 - 12.1.15 NORWAY 297
 - 12.1.16 REST OF EUROPE 305
- 13 EUROPE CANCER IMMUNOTHERAPY MARKET, COMPANY LANDSCAPE 306
 - 13.1 COMPANY SHARE ANALYSIS: EUROPE
- 14 SWOT ANALYSIS 307
- 15 COMPANY PROFILES 308
 - 15.1 MERCK & CO., INC. 308
 - 15.1.1 COMPANY SNAPSHOT 308
 - 15.1.2 REVENUE ANALYSIS 308
 - 15.1.3 COMPANY SHARE ANALYSIS 309
 - 15.1.4 PRODUCT PORTFOLIO 309
 - 15.1.5 RECENT DEVELOPMENTS 309
 - 15.2 F. HOFFMANN-LA ROCHE LTD 310
 - 15.2.1 COMPANY SNAPSHOT 310

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

15.2.2	REVENUE ANALYSIS	310
15.2.3	COMPANY SHARE ANALYSIS	311
15.2.4	PRODUCT PORTFOLIO	311
15.2.5	RECENT DEVELOPMENTS	311
15.3	BRISTOL-MYERS SQUIBB COMPANY	313
15.3.1	COMPANY SNAPSHOT	313
15.3.2	REVENUE ANALYSIS	313
15.3.3	COMPANY SHARE ANALYSIS	314
15.3.4	PRODUCT PORTFOLIO	314
15.3.5	RECENT DEVELOPMENTS	315
15.4	JANSSEN EUROPE SERVICES, LLC	316
15.4.1	COMPANY SNAPSHOT	316
15.4.2	REVENUE ANALYSIS	316
15.4.3	COMPANY SHARE ANALYSIS	317
15.4.4	PRODUCT PORTFOLIO	317
15.4.5	RECENT DEVELOPMENTS	318
15.5	ASTRAZENECA	319
15.5.1	COMPANY SNAPSHOT	319
15.5.2	REVENUE ANALYSIS	319
15.5.3	COMPANY SHARE ANALYSIS	320
15.5.4	PRODUCT PORTFOLIO	320
15.5.5	RECENT DEVELOPMENTS	321
15.6	ABBVIE INC.	322
15.6.1	COMPANY SNAPSHOT	322
15.6.2	PIPELINE PORTFOLIO	322
15.6.3	RECENT DEVELOPMENTS	322
15.7	AMGEN INC.	323
15.7.1	COMPANY SNAPSHOT	323
15.7.2	REVENUE ANALYSIS	324
15.7.3	PIPELINE PORTFOLIO	324
15.7.4	PRODUCT PORTFOLIO	325
15.7.5	RECENT DEVELOPMENTS	325
15.8	ATARA BIOTHERAPEUTICS, INC.	326
15.8.1	COMPANY SNAPSHOT	326
15.8.2	PIPELINE PORTFOLIO	326
15.8.3	RECENT DEVELOPMENTS	326
15.9	BAYER AG	327
15.9.1	COMPANY SNAPSHOT	327
15.9.2	PIPELINE PORTFOLIO	327
15.9.3	RECENT DEVELOPMENTS	327
15.10	CELLEX THERAPEUTICS	329
15.10.1	COMPANY SNAPSHOT	329
15.10.2	PIPELINE PORTFOLIO	329
15.10.3	RECENT DEVELOPMENTS	329
15.11	CELLECTIS	330
15.11.1	COMPANY SNAPSHOT	330
15.11.2	PIPELINE PORTFOLIO	330

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 15.11.3 RECENT DEVELOPMENTS 330
- 15.12 GILEAD SCIENCES, INC. 331
 - 15.12.1 COMPANY SNAPSHOT 331
 - 15.12.2 REVENUE ANALYSIS 331
 - 15.12.3 PRODUCT PORTFOLIO 332
 - 15.12.4 RECENT DEVELOPMENTS 332
- 15.13 GSK PLC. 333
 - 15.13.1 COMPANY SNAPSHOT 333
 - 15.13.2 REVENUE ANALYSIS 333
 - 15.13.3 PRODUCT PORTFOLIO 334
 - 15.13.4 RECENT DEVELOPMENTS 334
- 15.14 INCYTE. 335
 - 15.14.1 COMPANY SNAPSHOT 335
 - 15.14.2 REVENUE ANALYSIS 335
 - 15.14.3 PRODUCT PORTFOLIO 336
 - 15.14.4 RECENT DEVELOPMENTS 336
- 15.15 LILLY. 337
 - 15.15.1 COMPANY SNAPSHOT 337
 - 15.15.2 REVENUE ANALYSIS 338
 - 15.15.3 PRODUCT PORTFOLIO 338
 - 15.15.4 RECENT DEVELOPMENTS 339
- 15.16 NOVARTIS AG 340
 - 15.16.1 COMPANY SNAPSHOT 340
 - 15.16.2 REVENUE ANALYSIS 340
 - 15.16.3 PIPELINE PORTFOLIO 341
 - 15.16.4 PRODUCT PORTFOLIO 341
 - 15.16.5 RECENT DEVELOPMENTS 341
- 15.17 PFIZER INC. 342
 - 15.17.1 COMPANY SNAPSHOT 342
 - 15.17.2 REVENUE ANALYSIS 342
 - 15.17.3 PRODUCT PORTFOLIO 343
 - 15.17.4 RECENT DEVELOPMENTS 343
- 16 QUESTIONNAIRE 344
- 17 RELATED REPORTS 348

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Europe Cancer Immunotherapy Market - Industry Trends and Forecast to 2033

Market Report | 2023-12-01 | 348 pages | Data Bridge Market Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$3500.00
	Corporate Users License	\$4200.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-12"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com